BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18318660)

  • 21. Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition.
    Jiang L; Oldenburg E; Kromann-Hansen T; Xu P; Jensen JK; Andreasen PA; Huang M
    Biochim Biophys Acta Gen Subj; 2018 Sep; 1862(9):2017-2023. PubMed ID: 29959058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An ester bond linking a fragment of a serine proteinase to its serpin inhibitor.
    Egelund R; Rodenburg KW; Andreasen PA; Rasmussen MS; Guldberg RE; Petersen TE
    Biochemistry; 1998 May; 37(18):6375-9. PubMed ID: 9572853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterising the Subsite Specificity of Urokinase-Type Plasminogen Activator and Tissue-Type Plasminogen Activator using a Sequence-Defined Peptide Aldehyde Library.
    Li CY; de Veer SJ; Law RHP; Whisstock JC; Craik DJ; Swedberg JE
    Chembiochem; 2019 Jan; 20(1):46-50. PubMed ID: 30225958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
    Nagase K; Kobayashi H; Yoshikawa E; Kurita N
    J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutagenesis at Pro309 of single-chain urokinase-type plasminogen activator alters its catalytic properties.
    Sun Z; Liu JN
    Proteins; 2005 Dec; 61(4):870-7. PubMed ID: 16231330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The binding mechanism of a peptidic cyclic serine protease inhibitor.
    Jiang L; Svane AS; Sørensen HP; Jensen JK; Hosseini M; Chen Z; Weydert C; Nielsen JT; Christensen A; Yuan C; Jensen KJ; Nielsen NC; Malmendal A; Huang M; Andreasen PA
    J Mol Biol; 2011 Sep; 412(2):235-50. PubMed ID: 21802428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA).
    Matthews H; Ranson M; Tyndall JD; Kelso MJ
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6760-6. PubMed ID: 21978672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
    Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
    J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.
    Wendt MD; Rockway TW; Geyer A; McClellan W; Weitzberg M; Zhao X; Mantei R; Nienaber VL; Stewart K; Klinghofer V; Giranda VL
    J Med Chem; 2004 Jan; 47(2):303-24. PubMed ID: 14711304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate.
    Jiang L; Andersen LM; Andreasen PA; Chen L; Huang M
    Biochim Biophys Acta; 2016 Mar; 1860(3):599-606. PubMed ID: 26691138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.
    Behrens MA; Botkjaer KA; Goswami S; Oliveira CL; Jensen JK; Schar CR; Declerck PJ; Peterson CB; Andreasen PA; Pedersen JS
    J Mol Biol; 2011 Aug; 411(2):417-29. PubMed ID: 21669207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines.
    Fish PV; Barber CG; Brown DG; Butt R; Collis MG; Dickinson RP; Henry BT; Horne VA; Huggins JP; King E; O'Gara M; McCleverty D; McIntosh F; Phillips C; Webster R
    J Med Chem; 2007 May; 50(10):2341-51. PubMed ID: 17447747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding of nonphysiological protein and peptide substrates to proteases: differences between urokinase-type plasminogen activator and trypsin and contributions to the evolution of regulated proteolysis.
    Bergstrom RC; Coombs GS; Ye S; Madison EL; Goldsmith EJ; Corey DR
    Biochemistry; 2003 May; 42(18):5395-402. PubMed ID: 12731881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel genetically-encoded bicyclic peptide inhibitor of human urokinase-type plasminogen activator with better cross-reactivity toward the murine orthologue.
    Mazzocato Y; Perin S; Morales-Sanfrutos J; Romanyuk Z; Pluda S; Acquasaliente L; Borsato G; De Filippis V; Scarso A; Angelini A
    Bioorg Med Chem; 2023 Nov; 95():117499. PubMed ID: 37879145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The crystal structures of 3-TAPAP in complexes with the urokinase-type plasminogen activator and picrate.
    Zesławska E; Jacob U; Stürzebecher J; Oleksyn BJ
    Bioorg Med Chem Lett; 2006 Jan; 16(1):228-34. PubMed ID: 16202591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator.
    Joossens J; Van der Veken P; Lambeir AM; Augustyns K; Haemers A
    J Med Chem; 2004 May; 47(10):2411-3. PubMed ID: 15115382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties.
    Joossens J; Ali OM; El-Sayed I; Surpateanu G; Van der Veken P; Lambeir AM; Setyono-Han B; Foekens JA; Schneider A; Schmalix W; Haemers A; Augustyns K
    J Med Chem; 2007 Dec; 50(26):6638-46. PubMed ID: 18052026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ecotin: a serine protease inhibitor with two distinct and interacting binding sites.
    Yang SQ; Wang CI; Gillmor SA; Fletterick RJ; Craik CS
    J Mol Biol; 1998 Jun; 279(4):945-57. PubMed ID: 9642073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
    Sperl S; Jacob U; Arroyo de Prada N; Stürzebecher J; Wilhelm OG; Bode W; Magdolen V; Huber R; Moroder L
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5113-8. PubMed ID: 10805774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors.
    Zeslawska E; Jacob U; Schweinitz A; Coombs G; Bode W; Madison E
    J Mol Biol; 2003 Apr; 328(1):109-18. PubMed ID: 12684001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.